Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00751777 · ClinicalTrials.gov registry record · Phase 2
Traveler's Diarrhea (TD) Automated Process
A Phase 2 study, sponsored by Intercell USA.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00751777 is a Phase 2 study that has completed, run by Intercell USA. The registered enrollment target is 120 participants.
The verdict
NCT00751777, a Phase 2 study, has completed, sponsored by Intercell USA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL heat-labile enterotoxin of E. coli (LT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00751777
The ClinicalTrials.gov registry entry for NCT00751777 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercell USA, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00751777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00751777 about?
NCT00751777 is a clinical study titled "Traveler's Diarrhea (TD) Automated Process". To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.
What is the current status of trial NCT00751777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2008-09. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00751777?
The interventions under investigation include: Placebo (BIOLOGICAL), heat-labile enterotoxin of E. coli (LT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00751777?
This trial is sponsored by Intercell USA, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.